Golden Biotechnology Corp. acquired a new patent for treating arteriosclerosis granted by the Japan Patent Office (JPO) for “Methods and Compositions for Treating Arteriosclerotic Vascular Diseases.”

Golden Biotechnology Corp. (GBC) is a Taiwan-based international company focusing on the discovery of novel drugs and the manufacturing of dietary supplements. GBC has acquired over one hundred patents for many indications worldwide for Antroquinonol, a novel small molecule drug developed by GBC undergoing multi-national clinical trials for NSCLC (Non- Small Cell Lung Cancer). GBC aims to discover new drugs, especially in anti-cancer and other indications like anti-atherosclerosis drugs developed from the vast database from the screening platforms established in GBC.

Atherosclerosis (known as an arteriosclerotic vascular disease or ASVD) is an illness in which an arterial wall becomes thick as a result of accumulation of adipose substances like cholesterol. It is a condition in which a chronic inflammatory reaction occurs on the walls of blood vessel enabled by lipoproteins.

Atherosclerosis often causes hardening and plugging of the arteries caused by the formation of plaques in the artery. Although atherosclerosis influences the whole artery system, most activity happens in blood vessels like the coronary artery, renal artery, femoral artery, cerebral arteries and carotid artery where blood pressure becomes high.

GBC’s new arteriosclerosis patent is the use of a therapeutically effective amount of the compounds of indicated structures for treating atherosclerosis. The structures of the compounds also claim to inhibit PDGF-stimulated smooth muscle cell proliferation or migration, reducing neointima formation, lowering low-density lipoprotein (LDL) cholesterol and maintaining a normal low-density lipoprotein (LDL) cholesterol level in the blood.

Atherosclerosis is associated with coronary artery disease, aneurysms, myocardial infarction, embolism, stroke, thrombosis and other related diseases, which are also covered in the patent.